[Gopten (trandolapril) in the treatment of chronic heart failure in patients with ischemic heart disease]. 1998

I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia

OBJECTIVE To investigate clinical efficacy of angiotensin-converting enzyme inhibitor trandolapril and its effects on myocardial function. METHODS 20 patients with ischemic heart disease (IHD) aged 33-74 years with chronic cardiac failure NYHA class II-IV. 4 of them survived myocardial infarction. In addition to the routine tests, the patients underwent echocardiography, radionuclide ventriculography. Trandolapril was given once a day for 28 days in a dose 2 mg, then a repeat examination was performed. RESULTS Trandolapril produced a subjective effect in 80% of patients. There was also improvement of hemodynamic parameters, an increase in the ejection fraction, sensitivity to nitroglycerin, decline of asynchrony. The drug was well tolerated. CONCLUSIONS Trandolapril (Gopten) is effective in IHD patients with chronic cardiac failure.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
January 2004, Kardiologiia,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
June 1998, Likars'ka sprava,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
January 1998, Terapevticheskii arkhiv,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
September 2003, Polskie Archiwum Medycyny Wewnetrznej,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
September 1998, Cardiovascular drugs and therapy,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
September 1989, Vrachebnoe delo,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
September 1989, Vrachebnoe delo,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
January 2002, Kardiologiia,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
August 1986, Vrachebnoe delo,
I M Kakhnovskiĭ, and I G Fomina, and E L Ostroumov, and V M Lepeshkov, and N E Gaĭdamakina, and O V Kaveshnikova, and Z S Markova, and E L Lugovaia
July 1984, Vrachebnoe delo,
Copied contents to your clipboard!